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Abstract: Chronic obstructive pulmonary disease (COPD) is characterized by an abnormal 
inflammatory response in the lungs caused by the inhalation of noxious particles and gases. 
The airway epithelium has a protective function against these harmful agents by maintaining a 
physical barrier and by secreting defensive proteins, such as bactericidal/permeability-increasing 
fold-containing (BPIF) proteins, BPIFA1 and BPIFB1. However, inconsistent data regarding 
BPIFA1 expression in smokers and COPD patients have been reported to date. Therefore, we 
investigated the expression of BPIFA1 and BPIFB1 in a large cohort of never-smokers and 
smokers with and without COPD, both on the messenger RNA (mRNA) level in lung tissue and 
on the protein level in airway epithelium. Furthermore, we examined the correlation between 
BPIFA1 and BPIFB1 levels, goblet cell hyperplasia, and lung function measurements. BPIFA1 
and BPIFB1 mRNA expressions were significantly increased in stage III–IV COPD patients 
compared with stage II COPD patients and subjects without COPD. In addition, protein levels 
in COPD patients were significantly increased in comparison with subjects without COPD. 
BPIFA1 and BPIFB1 levels were inversely correlated with measurements of airflow limitation 
and positively correlated with goblet cell hyperplasia. In addition, by the use of immunofluo-
rescence double staining, we demonstrated the expression of BPIFB1 in goblet cells. In conclu-
sion, we show that BPIFA1 and BPIFB1 levels are elevated in COPD patients and correlate 
with disease severity.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a highly prevalent lung disease, 
characterized by gradually progressing and persistent airflow limitation. In subjects 
prone to develop COPD, the inhalation of noxious particles and gases causes lung 
inflammation, resulting in small airway obstruction and emphysema.1 The major 
risk factor for COPD is cigarette smoking,2 and multiple interrelated mechanistic 
pathways have been identified, varying from exaggerated chronic inflammation to 
an imbalanced oxidative stress response, trying to explain the damaging nature of 
cigarette smoke and other detrimental air pollutants.3,4 Unfortunately, currently, no 
disease-modifying therapy exists for COPD; hence, treatment is mainly focused on 
relieving the symptoms.
Airway epithelial cells form a first line of defense against harmful pathogens and 
irritants that enter the respiratory tract. Aside from maintaining a physical barrier, 
they create a chemical barrier by secreting protective proteins, such as bactericidal/
permeability-increasing fold-containing (BPIF) family members BPIFA1 and 
BPIFB1, formerly known as SPLUNC1 and LPLUNC1, respectively. All the 
members of the BPIF superfamily share the three-dimensional structure of the 
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bactericidal/permeability-increasing protein (BPI). BPIFA 
proteins are classified as containing a single BPIF domain, 
whereas BPIFB proteins contain two of these domains.5,6
BPIFA1 is localized to the respiratory epithelium and 
the submucosal glands of the upper airways.7,8 BPIFB1 is 
detected in the trachea and in epithelium and submucosal 
glands of larger and some smaller airways. BPIFA1 and 
BPIFB1 are absent from the alveolar regions of healthy 
lung, and both proteins exhibit limited expression in healthy 
airways.9,10 Interestingly, the expression and secretion of 
both proteins are dependent upon the differentiation status of 
the epithelial cell population, as demonstrated by the study 
of primary human lung cell cultures grown at air–liquid 
interface.8,9,11,12 BPIFB1 is localized to goblet cells, whereas 
BPIFA1 originates from nonciliated nongoblet epithelial 
cells.7,9,13 This mutually exclusive localization appears to be 
retained in cystic fibrosis (CF) lung disease.10
Conflicting data regarding BPIFA1 levels in relation 
to cigarette smoke exposure and COPD status have been 
reported. For instance, measurements on a limited number of 
subjects indicated increased levels of BPIFA1 in the airway 
epithelium and sputum of COPD patients compared with non-
COPD patients.14,15 However, lower BPIFA1 levels in airway 
epithelial cells and nasal lavage fluid of current smokers com-
pared with nonsmokers have also been reported.16–18 These 
discrepancies may have arisen due to the limited number of 
patient samples used in the studies and the semi-quantitative 
nature of the analysis, with most of the data coming from 
Western blotting. BPIFB1, on the other hand, seems to be 
consistently upregulated in several respiratory diseases. 
BPIFB1 levels were higher in the lungs of CF patients, in a 
mouse model of CF10 and in bronchoalveolar lavage (BAL) 
fluid of asthma patients after segmental allergen challenge.19 
In addition, recent studies showed an elevation of secreted 
BPIFB1 in the sputum of COPD patients compared with 
smokers and nonsmokers.13,20 As BPIFB1 is predominantly 
localized to a population of goblet cells,9 elevations in levels 
in COPD may be a reflection of the increased number of these 
cells in the airways.
To address some of these inconsistencies, in this study, we 
quantified the expression of BPIFA1 and BPIFB1 in a large 
cohort of never-smokers, smokers without airway limitation, 
and smokers with COPD. We measured the messenger RNA 
(mRNA) levels of BPIFA1 and BPIFB1 by quantitative real-
time polymerase chain reaction (qRT-PCR) in lung tissue, 
and we analyzed the protein expression levels in airway 
epithelium using immunohistochemistry (in 92 subjects and 
94 subjects, respectively). In addition, we quantified goblet 
cells in the airway epithelium and correlated their numbers 
with the levels of BPIFA1 and BPIFB1.
Methods
human study populations
Lung resection specimens were obtained from patients 
undergoing surgery for solitary pulmonary tumors (Ghent 
University Hospital, Ghent, Belgium) or from explant lungs 
of end-stage COPD patients undergoing lung transplantation 
(University Hospital Gasthuisberg, Leuven, Belgium). For 
qRT-PCR and immunohistochemical analysis of paraffin-
embedded sections, 92 and 94 subjects were included, respec-
tively (Tables 1 and 2); 68 patients are included in both the 
qRT-PCR and immunohistochemical analysis. Preoperative 
Table 1 Characteristics of study population (qrT-PCr study)
 Never- 
smokers
Smokers 
without COPD
COPD 
GOLD II
COPD 
GOLD III–IV
number 18 26 34 14
gender ratio (male/female) 6/12# 19/7# 31/3# 8/6#
age (years) 65 (56–70) 63 (55–70) 66 (58–69)§ 56 (54–60)*,§,‡
Current smoker/ex-smoker – 16/10 22/12 0/14
smoking history (PY) 0 (0–0) 28 (15–45)* 45 (40–60)*,§ 30 (25–30)*,‡
FeV1 post-BD (l) 2.7 (2.3–3.2) 2.7 (2.3–3.3) 2.0 (1.8–2.4)*
,§ 0.7 (0.7–0.9)*,§,‡
FeV1 post-BD (% predicted) 102 (92–116) 95 (93–112) 68 (61–75)*
,§ 26 (20–32)*,§,‡
FeV1/FVC post-BD (%) 78 (75–83) 75 (71–79)* 56 (53–60)*
,§ 32 (27–35)*,§,‡
DlCO (% predicted) 90 (80–105) 80 (61–102) 67 (51–87)* 35 (33–41)*
,§,‡
KCO (% predicted) 103 (88–123) 91 (68–107)* 87 (62–108)* 59 (50–65)*
,§,‡
ICs (yes/no) 0/18# 1/25# 15/19# 13/1#
Notes: n=92. Data are presented as median (IQr). Mann–Whitney U-test: *p,0.05 versus never-smokers; §p,0.05 versus smokers without COPD; ‡p,0.05 versus COPD 
gOlD II. Fisher’s exact test: #p,0.001. ‘–’ indicates not applicable.
Abbreviations: COPD, chronic obstructive pulmonary disease; DlCO, diffusing capacity of the lung for carbon monoxide; FeV1, forced expiratory volume in 1 second; 
FVC, forced vital capacity; gOlD, global Initiative for Chronic Obstructive lung Disease; ICs, inhaled corticosteroids; IQr, interquartile range; KCO, the ratio of DlCO to 
alveolar volume; post-BD, post-bronchodilator; PY, pack years; qrT-PCr, quantitative real-time polymerase chain reaction.
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spirometry measurements, diffusion capacity tests, and ques-
tionnaires were used to categorize patients as never-smokers 
with normal lung function, smokers without airflow limita-
tion, or patients with COPD. COPD severity was defined 
according to the Global Initiative for Chronic Obstructive 
Lung Disease (GOLD) classification.21 Lung tissue of patients 
diagnosed with solitary pulmonary tumor was obtained at 
maximum distance from the pulmonary lesions and without 
signs of retro-obstructive pneumonia or tumor invasion. 
None of the patients operated for malignancy were treated 
with neoadjuvant chemotherapy. Written informed consent 
was obtained from all subjects. This study was approved 
by the medical ethical committees of the Ghent University 
Hospital (2011/14) and the University Hospital Gasthuisberg 
Leuven (S51577).
qrT-PCr
Lung tissue blocks were submersed in RNA later (Qiagen, 
Hilden, Germany) and stored at -80°C. RNA extraction 
was performed by using the miRNeasy Mini kit (Qiagen). 
Next, cDNA was prepared by using the iScript Advanced 
cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA). Taq-
Man® Gene Expression Assays (Applied Biosystems, Forster 
City, CA, USA) were used to measure the expression of the 
target genes BPIFA1 and BPIFB1 and the reference genes 
glyceraldehyde-3-phosphate dehydrogenase, hypoxanthine 
phosphoribosyltransferase-1, and succinate dehydrogenase 
complex flavoprotein subunit A. qRT-PCRs were performed 
in duplicate, and a standard curve was created by serial 
dilutions of a mixture of all samples. The amplifications 
were performed by using a LightCycler 96 detection system 
(Roche, Basel, Switzerland). The amplification conditions 
consisted of a preincubation step (600 s at 95°C), followed 
by 50 cycles of a two-step amplification (10 s at 95°C and 
15 s at 60°C). Data were analyzed using the standard curve 
method, and the expressions of BPIFA1 and BPIFB1 were 
calculated relative to the expression of the three reference 
genes, using the geNorm applet (http://medgen.ugent.
be/~jvdesomp/genorm/).22
Generation of a human-specific BPIFA1 
antibody
An affinity-purified, peptide-specific, rabbit polyclonal anti-
body against human BPIFA1 was generated by Eurogentec 
(Seraing, Belgium). The peptide sequences used corre-
sponded to amino acids 192–207 (DGLGPLPIQGLLDSL). 
This peptide has minimal sequence conservation between 
man and mouse and exhibits no similarity with other mem-
bers of the BPIF protein family. It also has no significant 
sequence identity with any other human proteins. Antibodies 
were validated by Western blotting using apical secretions 
from air–liquid interface cultures of human bronchial epi-
thelial cells as previously described.10 The BPIFA1 antibody 
was used to probe two air–liquid interface wash samples (A84 
and A42) at a final dilution of 1:200.
Immunohistochemistry
To analyze BPIFA1 and BPIFB1 in lung resection speci-
mens, paraffin-embedded sections were subjected to either 
BPIFA1 or BPIFB1 staining. For this purpose, 3-µm-thick 
paraffin-embedded sections were cut on poly-L-lysin-coated 
slides. The sections were subjected to antigen retrieval using 
Table 2 Characteristics of study population (immunohistochemical study)
Never- 
smokers
Smokers 
without COPD
COPD 
GOLD II
COPD GOLD 
III–IV
number 18 28 34 14
gender ratio (male/female) 5/13# 20/8# 32/2# 5/9#
age (years) 65 (61–71) 66 (57–71) 66 (59–69) 58 (55–60)*,§,‡
Current smoker/ex-smoker – 16/12 21/13 0/14
smoking history (PY) 0 (0–0) 34 (15–49)* 45 (39–60)*,§ 36 (30–42)*,‡
FeV1 post-BD (l) 2.4 (2.0–3.0) 2.7 (2.3–3.3) 2.1 (1.8–2.4)*
,§ 0.6 (0.5–0.9)*,§,‡
FeV1 post-BD (% predicted) 107 (92–118) 95 (93–113) 69 (61–75)*
,§ 24 (20–34)*,§,‡
FeV1/FVC post-BD (%) 79 (74–83) 77 (72–79) 56 (50–61)*
,§ 31 (26–36)*,§,‡
DlCO (% predicted) 88 (80–104) 83 (65–104) 71 (53–87)* 33 (28–36)*
,§,‡
KCO (% predicted) 94 (86–122) 96 (79–106) 90 (67–108)* 47 (42–57)*
,§,‡
ICs (yes/no) 1/17# 2/26# 14/20# 14/0#
Notes: n=94. Data are presented as median (IQr). Mann–Whitney U-test: *p,0.05 versus never-smokers; §p,0.05 versus smokers without COPD; ‡p,0.05 versus COPD 
gOlD II. Fisher’s exact test: #p,0.001. ‘–’ indicates not applicable.
Abbreviations: COPD, chronic obstructive pulmonary disease; DlCO, diffusing capacity of the lung for carbon monoxide; FeV1, forced expiratory volume in 1 second; 
FVC, forced vital capacity; gOlD, global Initiative for Chronic Obstructive lung Disease; ICs, inhaled corticosteroids; IQr, interquartile range; KCO, the ratio of DlCO to 
alveolar volume; post-BD, post-bronchodilator; PY, pack years.
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either EDTA buffer (BPIFA1) or citrate buffer (BPIFB1). 
Next, endogenous peroxidase activity was blocked using 3% 
hydrogen peroxide in phosphate-buffered saline (PBS). Then, 
tissue sections were incubated with Boehringer blocking 
agent (Roche) with 0.3% Triton™ X-100 (Sigma-Aldrich, 
St Louis, MO, USA), followed by 24-hour incubation with 
rabbit polyclonal anti-BPIFA1 or rabbit polyclonal anti-
BPIFB19 or isotype rabbit IgG (Abcam, Cambridge, UK). 
Next, the slides were incubated for 30′ with PowerVision 
poly-horseradish peroxidase anti-rabbit (Immunologic, 
Duiven, the Netherlands), followed by staining with 3,3′-
diaminobenzidine (Dako, Glostrup, Denmark) for 10 minutes. 
Afterward, the slides were counterstained with Mayer’s 
hematoxylin (Sigma-Aldrich). Finally, the sections were 
dehydrated and mounted with distrene plasticizer xylene 
(Prosan, Merelbeke, Belgium). Photomicrographs of the air-
ways in the sections were taken, and the amount of BPIFA1 
and BPIFB1 in the airway epithelium was quantified, in a 
blinded manner, using the Axiovision software from Zeiss 
(Oberkochen, Germany). The amount of BPIFA1 and BPIFB1 
was normalized to the length of the basement membrane.
Immunofluorescence staining
Immunofluorescence staining was performed on paraffin-
embedded sections of human lung tissue of a COPD GOLD II 
patient. The sections were subjected to antigen retrieval using 
EDTA buffer (Dako). After washing steps with PBS, the 
sections were incubated with Boehringer blocking agent 
(Roche) with 0.3% Triton X-100 (Sigma-Aldrich). Primary 
antibodies were added for 24 hours: rabbit anti-BPIFA1, 
rabbit anti-BPIFB1,9 mouse anti-MUC5AC (Abcam), mouse 
anti-P63 (Abcam), isotype rabbit IgG (Novus Biologicals, 
Littleton, CO, USA), isotype mouse IgG2a (BD Biosci-
ences, San Diego, CA, USA), and isotype mouse IgG1 (BD 
Biosciences). Wash steps were performed, and the sections 
were incubated with secondary antibodies: donkey anti-rabbit 
Alexa Fluor 555 (Thermo Fisher Scientific, Waltham, MA, 
USA), donkey anti-mouse Alexa Fluor 488 (Thermo Fisher 
Scientific), and DAPI (Thermo Fisher Scientific). Finally, the 
sections were mounted with fluorescence mounting medium 
(Dako). Images were recorded with the Axiovision software 
from Zeiss. BPIFA1 and BPIFB1 were visualized as green, 
whereas MUC5AC and P63 were visualized as red.
goblet cell analysis
Tissue sections were stained with Periodic Acid–Schiff 
(PAS). PAS stains neutral mucins and acid mucins that 
contain significant amounts of sialic acid. Both major airway 
mucin proteins (MUC5AC and MUC5B) are stained by PAS. 
Goblet cells were counted using Axiovision software and 
were expressed as the number of goblet cells per millimeter 
basal membrane.
statistical analysis
Statistical analyses were performed by using Sigma Stat 
software (SPSS Statistics 23, Chicago, IL, USA) including 
Kruskal–Wallis, Mann–Whitney U-test, Fisher’s exact test, 
general linear model, and Spearman correlation analysis. 
Differences at p-values ,0.05 were considered to be signifi-
cant. Characteristics of the study population (Tables 1 and 2) 
are expressed as median and interquartile range.
Results
BPIFA1 and BPIFB1 mrna expressions 
are increased in lung tissue of patients 
with severe and very severe COPD
The expressions of BPIFA1 and BPIFB1 in lung tissue were 
analyzed by qRT-PCR in 92 subjects (Table 1) and were sig-
nificantly increased in patients with severe and very severe 
COPD (GOLD stage III–IV) compared with patients with 
mild-to-moderate COPD (GOLD stage II), smokers without 
airway limitation, and never-smokers (Figure 1A and B). 
Furthermore, the mRNA expressions of both BPIFA1 and 
BPIFB1 were significantly and inversely correlated with 
lung function parameters of airway obstruction (forced 
expiratory volume in 1 second [FEV
1
] and FEV
1
/forced 
vital capacity [FVC] post-bronchodilator [BD]) and with 
the diffusing capacity of the lungs (diffusing capacity of 
the lung for carbon monoxide [D
LCO
] and the ratio of D
LCO
 
to alveolar volume [K
CO
]; Figure S1). To evaluate the effect 
of different parameters (age, gender, COPD status, smoking 
status, and use of inhaled corticosteroids) on the expressions 
of BPIFA1 and BPIFB1, we performed linear regression 
analysis. Severe COPD status is the only significant 
independent determinant for BPIFA1 and BPIFB1 mRNA 
expressions (Tables S1 and S2).
BPIFa1 and BPIFB1 protein levels are 
increased in airway epithelium of patients 
with COPD
To study the expression of BPIFA1, we generated an affinity-
purified, peptide-specific, rabbit polyclonal antibody against 
human BPIFA1. To validate the BPIFA1 antibody, it was 
used to probe two air–liquid interface wash samples (A84 
and A42) at a final dilution of 1:200 (Figure 2).
The protein expressions of BPIFA1 and BPIFB1 in 
airway epithelium were analyzed by immunohistochemistry 
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in 94 subjects (Table 2). Immunohistochemical staining of 
BPIFA1 is localized to the airway epithelium with no evidence 
of staining in peripheral lung tissue (Figure 3A–F). Protein 
levels of BPIFA1 in airway epithelium of COPD patients 
(stage II and stage III–IV) were significantly increased 
in comparison with subjects without COPD. In addition, 
BPIFA1 protein expression was increased in the airway 
epithelium of control smokers compared with never-smokers 
(Figure 3G).
Immunohistochemical staining of BPIFB1 is detected 
in the airway epithelium (Figure 4A–F). As with BPIFA1, 
there was no staining in the alveolar tissues. BPIFB1 protein 
staining in the airway epithelium was significantly increased 
in patients with COPD compared with subjects without 
COPD (Figure 4G).
Importantly, both BPIFA1 and BPIFB1 protein staining 
was significantly inversely correlated with FEV
1
 and FEV
1
/
FVC post-BD (Figure 5). In addition, BPIFA1 protein was 
significantly negatively correlated with D
LCO
 and K
CO
, while 
BPIFB1 protein was not (Figure S2). The influence of age, 
gender, COPD status, smoking status, and use of inhaled 
corticosteroids on protein expressions of both BPIFA1 and 
BPIFB1 was determined by linear regression analysis. COPD 
status was the main determinant for BPIFA1 and BPIFB1 
protein staining. BPIFA1 protein was additionally influenced 
by the smoking status (Tables S3 and S4).
localization of BPIFa1 and BPIFB1 
in the airway epithelium by double 
immunofluorescence staining
To know which cell types are responsible for the production 
of BPIFA1 and BPIFB1, we performed double staining of 
these proteins with two different epithelial cell markers in 
a COPD GOLD II patient. We performed double staining 
for P63 (marker for basal cells) and BPIFA1 or BPIFB1. 
We did not see any BPIFA1 or BPIFB1 staining in P63+ basal 
cells (Figure 6G–L). In addition, we also performed double 
staining for MUC5AC and BPIFA1 or BPIFB1. MUC5AC 
is an abundantly expressed mucin localized to goblet cells. 
We observed strongly positive double staining for MUC5AC 
and BPIFB1 (Figure 6D–F), implicating the production of 
BPIFB1 by goblet cells and no or only very faint double 
staining for MUC5AC and BPIFA1 (Figure 6A–C).
BPIFa1 and BPIFB1 protein levels in 
airway epithelium correlate significantly 
with goblet cell hyperplasia
Figure 7A–D shows representative images of PAS staining of 
the airway epithelium of a never-smoker, a smoker without 
Figure 1 Pulmonary expression of BPIFA1 and BPIFB1 mrna levels.
Notes: BPIFA1 (A) and BPIFB1 (B) mrna levels measured by qrT-PCr in the lung tissue of never-smokers (n=18), smokers without airflow limitation (n=26), patients with 
COPD gOlD II (n=34), and patients with COPD gOlD III–IV (n=14; *p,0.05, **p,0.01, ***p,0.005; Mann–Whitney U-test). Data were analyzed using the standard curve 
method, and the expressions of BPIFA1 and BPIFB1 were calculated relative to the expression of three reference genes (GAPDH, SDHA, and HPRT-1).
Abbreviations: BPIF protein, bactericidal/permeability-increasing fold-containing protein; COPD, chronic obstructive pulmonary disease; GAPDH, glyceraldehyde-3-
phosphate dehydrogenase; gOlD, global Initiative for Chronic Obstructive lung Disease; HPRT-1, hypoxanthine phosphoribosyltransferase-1; qrT-PCr, quantitative real-
time polymerase chain reaction; SDHA, succinate dehydrogenase complex flavoprotein subunit A.
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Figure 2 Generation of a human-specific BPIFA1 antibody.
Notes: An affinity-purified, peptide-specific, rabbit polyclonal antibody against 
human BPIFa1 was generated and validated by Western blotting using apical 
secretions from air–liquid interface cultures of human bronchial epithelial cells. The 
BPIFa1 antibody was used to probe two air–liquid interface wash samples (a84 
and A42) at a final dilution of 1:200. The black arrows indicate the positions of the 
molecular mass markers.
Abbreviation: BPIF protein, bactericidal/permeability-increasing fold-containing 
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COPD, a patient with COPD GOLD stage II, and a patient 
with COPD GOLD stage IV. The number of PAS-positive 
cells per millimeter basal membrane is significantly increased 
in COPD patients compared with subjects without COPD 
(Figure 7E). Staining of both BPIFA1 and BPIFB1 protein 
in the airway epithelium was significantly correlated with 
the number of goblet cells (Figure 7F–G).
Discussion
In this study, we used a large cohort to demonstrate that 
the mRNA expression in lung tissue and protein expression 
in the airway epithelium of both BPIFA1 and BPIFB1 are 
increased in patients with COPD compared with those with-
out COPD. Moreover, we show that BPIFA1 and BPIFB1 
levels are positively correlated with goblet cell hyperplasia 
Figure 3 BPIFa1 protein expression in airway epithelium. 
Notes: representative images of immunohistochemical staining for BPIFa1 in the airway epithelium of a never-smoker (A), a smoker without airflow limitation (B), isotype 
control (C), a patient with COPD gOlD II (D), and a patient with COPD gOlD IV (E, F). Quantification of BPIFA1 protein levels in the airway epithelium of never-
smokers (n=15), smokers without airflow limitation (n=28), patients with COPD gOlD II (n=32), and patients with COPD gOlD III–IV (n=11; **p,0.01, ***p,0.005; 
Mann–Whitney U-test) (G). 
Abbreviations: BPIF protein, bactericidal/permeability-increasing fold-containing protein; COPD, chronic obstructive pulmonary disease; gOlD, global Initiative for 
Chronic Obstructive lung Disease.
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and inversely correlated with lung function parameters 
of airflow limitation (FEV
1
 and FEV
1
/FVC). In addition, 
BPIFA1 levels are inversely correlated with lung diffusion 
capacity parameters (D
LCO
 and K
CO
).
Research into the expression of BPIFA1 in subjects 
with COPD has previously produced inconsistent results. 
In accordance with our data, increased BPIFA1 expression 
in airway epithelium and increased BPIFA1 protein levels in 
sputum samples were observed in subjects with COPD com-
pared with those without.14,15 In contrast, another study 
reported reduced levels of BPIFA1 in BAL fluid of smokers 
with and without COPD compared with controls.18 In addi-
tion, Steiling et al demonstrated increased expression of 
BPIFA1 in airway epithelial cells of never-smokers com-
pared with current smokers.16 Substantial variability in the 
number of subjects studied and a wide range of techniques 
used to determine the level of BPIFA1 are probably in part 
responsible for these discrepancies. In addition, BPIFA1 is 
degraded by neutrophil elastase,18 and this might influence 
levels in COPD sputum and BAL fluid. It is important to 
reiterate that, although both of these proteins are commonly 
considered to be highly expressed in the airways, in fact 
Figure 4 BPIFB1 protein expression in airway epithelium.
Notes: representative images of immunohistochemical staining for BPIFB1 in the airway epithelium of a never-smoker (A), a smoker without airflow limitation (B), isotype 
control (C), a patient with COPD gOlD II (D), and a patient with COPD gOlD IV (E, F). Quantification of BPIFB1 protein expression in the airway epithelium of never-
smokers (n=16), smokers without airflow limitation (n=26), patients with COPD gOlD II (n=31), and patients with COPD gOlD III–IV (n=13; **p,0.01, ***p,0.005; 
Mann–Whitney U-test) (G). 
Abbreviations: BPIF protein, bactericidal/permeability-increasing fold-containing protein; COPD, chronic obstructive pulmonary disease; gOlD, global Initiative for 
Chronic Obstructive lung Disease.
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neither protein is found at significant levels in the epithelium 
of the normal lung,10,13 an observation that is confirmed by 
the systematic quantitative immunohistochemical analysis 
presented here.
We showed an increase in the expression of BPIFB1 in 
COPD patients compared with subjects without COPD, at both 
the mRNA and the protein levels. This is consistent with the 
reports of significant increases in levels of BPIFB1 detected 
in sputum and lung tissue of COPD patients as determined 
by enzyme linked immunosorbent assay, Western blotting, 
and mass spectrometry.13,20 In addition, increased BPIFB1 
expression, especially in the terminal airways within paren-
chyma tissues, was observed in COPD patients compared with 
controls.23 Stratification into current smokers and ex-smokers 
in one study showed that the levels were only significantly 
higher in COPD patients who continued smoking.13
The levels of BPIFA1 and BPIFB1 are significantly 
inversely correlated with parameters of airflow limitation, 
and the levels of BPIFA1 are also significantly inversely 
correlated with parameters of lung diffusion capacity, which 
serve as a proxy for COPD disease severity and the amount 
of emphysema, respectively. Consistent with our data, in 
the study from Saferali et al,24 which studied a group of 
739 patients with smoking-related lung disease (mostly 
lung cancer and COPD patients), elevated BPIFA1 levels 
were significantly associated with decreased lung function. 
In the study by Gao et al, sputum BPIFB1 levels were also 
significantly negatively correlated with FEV
1
% predicted 
and FEV
1
/FVC%, at both the baseline and after a 4-year 
follow-up period.13
As it has been shown previously that both BPIFA1 and 
BPIFB1 are expressed in nonciliated cells,9,25,26 we performed 
colocalization staining of the two proteins with known cel-
lular markers of two types of nonciliated cells, MUC5AC 
and P63. MUC5AC is an abundantly expressed mucin local-
ized to goblet cells, and P63 is a marker for basal cells. Our 
data show strongly positive double staining for MUC5AC 
and BPIFB1 (Figure 6F) and suggest a limited colocaliza-
tion of MUC5AC and BPIFA1 (Figure 6C). In addition, 
we measured the number of goblet cells by means of PAS 
staining. As expected, the number of PAS-positive cells was 
significantly increased in COPD patients compared with 
patients without COPD. The data show that BPIFB1 levels 
were strongly positively correlated with the number of goblet 
cells, confirming a strong relationship between BPIFB1 and 
goblet cells as visualized with immunofluorescence staining. 
A previous work on late-stage CF lung tissue has also shown 
that both proteins are increased in the remodeled epithelium.10 
In this study, the two proteins continued to be expressed in 
different cell types, with BPIFA1 being found in a serous 
Figure 5 Correlation of BPIFA1 and BPIFB1 protein levels in airway epithelium and lung function parameters of airflow limitation.
Notes: spearman correlation analysis of BPIFa1 protein levels with post-bronchodilator values of FeV1 (A) and the ratio of FeV1 to FVC (FeV1/FVC) (B). spearman 
correlation analysis of BPIFB1 protein levels with post-bronchodilator values of FeV1 (C) and FeV1/FVC (D).
Abbreviations: BPIF protein, bactericidal/permeability-increasing fold-containing protein; FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity.




   %3
,)$
SU
RWHL
Q
P
 3E
P
)(9)9&
5 S
%




  )(9
%3,
)$
SUR
WHLQ
P
 3E
P
5 S
$





   
%3,
)%
SUR
WHLQ
P
 3E
P
)(9)9&
5 S
'





  
%3,
)%
SUR
WHLQ
P
 3E
P
)(9
5 S
&
International Journal of COPD 2018:13 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
19
expression of BPIFa1 and BPIFB1 in COPD patients
Figure 6 Localization of BPIFA1 and BPIFB1 expression in lung tissue by double immunofluorescence staining.
Notes: Immunofluorescence staining was performed on paraffin-embedded lung tissue of a COPD GOLD II patient for BPIFA1, BPIFB1, P63, and MUC5AC. Blue DAPI 
staining is used to stain the cell nucleus. Immunofluorescence staining of BPIFA1 and DAPI (A), MUC5aC and DaPI (B), the merge of the two previous stainings (C). 
Immunofluorescence staining of BPIFB1 and DAPI (D), MUC5aC and DaPI (E), the merge of the two previous stainings (F). BPIFB1 shows strong colocalization with 
MUC5AC, whereas colocalization of BPIFA1 and MUC5AC is limited. Immunofluorescence staining of BPIFA1 and DAPI (G), P63 and DaPI (H), the merge of the two 
previous stainings (I). Immunofluorescence staining of BPIFB1 and DAPI (J), P63 and DaPI (K), the merge of the two previous stainings (L). BPIFa1 and BPIFB1 are not 
localized in basal cells. 
Abbreviations: BPIF protein, bactericidal/permeability-increasing fold-containing protein; COPD, chronic obstructive pulmonary disease; gOlD, global Initiative for 
Chronic Obstructive lung Disease.
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Figure 7 Goblet cell quantification and correlation with BPIFA1 and BPIFB1 protein expression in airway epithelium.
Notes: representative images of Pas staining in a never-smoker (A), a smoker without airflow limitation (B), a patient with COPD gOlD II (C), and a patient with COPD 
gOlD IV (D). Quantification of the number of goblet cells in the airway epithelium of never-smokers (n=17), smokers without airflow limitation (n=28), patients with COPD 
gOlD II (n=32), and patients with COPD gOlD III–IV (n=11), as measured by the number of Pas+ cells per millimeter of basal membrane (*p,0.05, **p,0.01, ***p,0.005; 
Mann–Whitney U-test) (E). Correlation of BPIFa1 (F) and BPIFB1 (G) protein expression and the number of Pas+ cells in the airway epithelium.
Abbreviations: BPIF protein, bactericidal/permeability-increasing fold-containing protein; COPD, chronic obstructive pulmonary disease; gOlD, global Initiative for 
Chronic Obstructive lung Disease; Pas, Periodic acid–schiff.
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cell population that was distinct from the BPIFB1-expressing 
goblet cells.10 The same mutually exclusive localization is 
also seen in the murine CF model.10 Our data suggest that 
in COPD patients BPIFA1 can also be expressed in some 
goblet cells. In addition, we performed double staining for 
P63 (a marker for basal cells) and BPIFA1 or BPIFB1. 
As expected, we did not see any BPIFA1 or BPIFB1 stain-
ing in P63+ basal cells. This corresponds to the paper by 
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Mulay et al, which describes that BPIFA1 staining is absent 
in basal cells of mouse middle ear epithelial cells in air–liquid 
interface culture.26 BPIFA1 is an important player in airway 
protection, and given its expression in the upper airways, it 
is ideally located to exert this function. One major compo-
nent of BPIFA1’s protective role seems to be mediated by 
its antimicrobial actions.27 In addition, BPIFA1 plays a role 
in ion transport and regulation of the airway surface liquid. 
Abnormal mucus rheology, caused for example by enhanced 
epithelial sodium channel (ENaC) activity, results in airway 
obstruction and mucostasis, which in turn might lead to bac-
terial infections and subsequent increased inflammation in 
patients with COPD. This could contribute to a faster decline 
in lung function.3,28,29 BPIFA1 acts as a negative regulator of 
ENaC and might in this way be able to positively influence 
the airway surface liquid height and, concurrent with this, 
protect epithelial homeostasis.30,31 Consistent with this obser-
vation, BPIFA1 silencing using small interfering RNA tech-
nology in a model of nontypeable Haemophilus influenzae 
otitis media resulted in an impaired mucus transport and 
mucociliary clearance.32 In addition, genetic polymorphisms 
associated with lower BPIFA1 levels have also been associ-
ated with decreased lung function.24 Interestingly, BPIFA1 
levels are significantly higher in patients with CF compared 
with subjects without CF.33 Likewise, data from our study 
and other studies also indicate higher levels of BPIFA1 in 
COPD patients compared with non-COPD patients.14,15 This 
might suggest that BPIFA1 has a protective function in the 
airways and that patients with inflammatory diseases (CF and 
COPD) are in need of higher levels of this protein to conserve 
airway epithelial homeostasis in their inflamed lungs. Studies 
investigating the acute effects of inflammation and infection 
describe a fast release of the stored protein, followed by a 
temporarily decreased BPIFA1 expression.34 In addition, 
neutrophil elastase has been reported to degrade BPIFA1 in a 
dose-dependent manner.18 In COPD patients, where bacterial 
infections are common and neutrophil elastase is present in 
high amounts, the need for secreted BPIFA1 is elevated. Our 
hypothesis is that the airway epithelium responds to this need 
by increasing the production and storage of BPIFA1; hence, 
the elevated levels of airway epithelial BPIFA1 protein are 
found in our study. However, further studies investigating the 
function of BPIFA1 in the diseased lung are necessary.
The role of BPIFB1 has been less extensively studied. Due 
to its structural similarity with proteins involved in protection 
against Gram-negative bacteria (lipopolysaccharide-binding 
and BPIs), it has been suggested that BPIFB1 might also play 
a role in innate immune defense,35,36 although compelling 
functional data are lacking. As mentioned before, BPIFB1 
levels are elevated in the airways of patients with CF and also 
in βENaC-Tg mice, a murine model for CF.10 BPIFB1 staining 
in this model was associated with mucus obstruction, goblet 
cell metaplasia, and inflammation in the airways, suggesting 
that the increased BPIFB1 levels in the CF lung are a conse-
quence of this epithelial remodeling.10 Also in COPD patients, 
extended epithelial remodeling with goblet cell metaplasia and 
inflammation takes place, and the observed increase in BPIFB1 
levels in COPD patients could be a direct consequence of this. 
This idea is strengthened by the observation that the number of 
goblet cells correlates very strongly with the BPIFB1 protein 
levels in our study. It is possible that BPIFB1, similarly to its 
family member BPIFA1, also plays a role in airway protec-
tion, but the way that BPIFB1 is able to perform this function 
requires additional functional analysis.
We quantified BPIFA1 levels in a large COPD patient 
cohort. In addition, we report quantitative data on the expres-
sion of BPIFB1 in airway epithelium, which is a valuable 
addition to the data on BPIFB1 levels in induced sputum.13,20 
Moreover, we showed data on expressions of BPIFA1 and 
BPIFB1 at both the mRNA and protein levels and related 
these to different lung function measurements. By using 
D
LCO
 and K
CO
 values, we were able to correlate BPIFA1 and 
BPIFB1 expressions with an adequate measurement for the 
degree of emphysema. A limitation of our study is that we 
have data only on the BPIFA1 and BPIFB1 protein expres-
sions in the airway epithelium and not on the level of secreted 
proteins. We are also not able to comment on the role that 
submucosal gland secretion of these two proteins may play 
in modulating levels of the proteins in COPD. Both proteins 
are known to be present in submucosal glands7,9,14 and have 
been identified in gland mucus.37
Conclusion
We demonstrated that the mRNA and protein expressions 
of both BPIFA1 and BPIFB1 are increased in patients with 
COPD compared with those without COPD. Moreover, we 
showed that BPIFA1 and BPIFB1 expressions are correlated 
with goblet cell metaplasia and inversely correlated with 
lung function parameters of airway obstruction (FEV
1
 and 
FEV
1
/FVC). Future experiments are necessary to elucidate 
the function of BPIFA1 and BPIFB1, not only in the context 
of airway protection toward infectious agents, but also in a 
setting of exaggerated and imbalanced airway inflammation 
in COPD patients.
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Figure S1 Correlation of BPIFA1 and BPIFB1 mrna levels with different lung function parameters. 
Notes: spearman correlation analysis of BPIFA1 and BPIFB1 mrna levels with post-bronchodilator values of FeV1 (A, B), and the ratio of FeV1 to FVC (FeV1/FVC) (C, D), 
DlCO (E, F), and the ratio of DlCO to alveolar volume (KCO) (G, H). R
2= determination coefficient.
Abbreviations: BPIF protein, bactericidal/permeability-increasing fold-containing protein; DlCO, diffusing capacity of the lung for carbon monoxide; FeV1, forced expiratory 
volume in 1 second; FVC, forced vital capacity; KCO, the ratio of DlCO to alveolar volume.
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Table S2 general linear model for BPIFB1 mrna expression
Parameter B Standard 
error
t Significance
Intercept -2.8 1.878 -1.491 0.14
age 0.001 0.029 0.05 0.96
gender
Male 0.113 0.562 0.201 0.841
Female 0a
Inhaled corticosteroids
Inhaled corticosteroid use 0.347 0.712 0.487 0.627
no inhaled corticosteroid use 0a
smoking status
Yes 0.552 0.561 0.984 0.328
no (ex-smoker or never-smoker) 0a
COPD status
COPD III–IV 3.237 1 3.236 0.002
COPD II 0.307 0.647 0.475 0.636
Without COPD 0a
Notes: areference parameter is set to 0. linear regression analysis, where the natural logarithm of the mrna expression of BPIFB1 is designated as the dependent variable; 
gender as a fixed factor; COPD status, smoking status, and inhaled corticosteroids as random factors; and age as a covariate.
Abbreviation: COPD, chronic obstructive pulmonary disease.
Table S1 general linear model for BPIFa1 mrna expression
Parameter B Standard 
error
t Significance
Intercept -3.554 2.112 -1.682 0.096
age -0.012 0.033 -0.361 0.719
gender
Male 0.234 0.64 0.366 0.715
Female 0a
Inhaled corticosteroids
Inhaled corticosteroid use 0.736 0.818 0.9 0.371
no inhaled corticosteroid use 0a
smoking status
Yes 0.952 0.632 1.506 0.136
no (ex-smoker or never-smoker) 0a
COPD status
COPD III–IV 2.37 1.173 2.02 0.047
COPD II 0.256 0.719 0.356 0.723
Without COPD 0a
Notes: areference parameter is set to 0. linear regression analysis, where the natural logarithm of the mrna expression of BPIFa1 is designated as the dependent variable; 
gender as a fixed factor; COPD status, smoking status, and inhaled corticosteroids as random factors; and age as a covariate.
Abbreviation: COPD, chronic obstructive pulmonary disease.
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Table S3 general linear model for BPIFa1 protein expression
Parameter B Standard 
error
t Significance
Intercept -7.271 2.162 -3.363 0.001
age 0.026 0.033 0.789 0.432
gender
Male 0.425 0.622 0.684 0.496
Female 0a
Inhaled corticosteroids
Inhaled corticosteroid use 0.108 0.807 0.134 0.893
no inhaled corticosteroid use 0a
smoking status
Yes 1.339 0.585 2.289 0.025
no (ex-smoker or never-smoker) 0a
COPD status
COPD III–IV 4.069 1.211 3.359 0.001
COPD II 2.140 0.664 3.223 0.002
Without COPD 0a
Notes: areference parameter is set to 0. linear regression analysis, where the natural logarithm of the protein expression of BPIFa1 is designated as the dependent variable; 
gender as a fixed factor; COPD status, smoking status, and inhaled corticosteroids as random factors; and age as a covariate.
Abbreviation: COPD, chronic obstructive pulmonary disease.
Figure S2 Correlation of BPIFa1 and BPIFB1 protein levels with parameters of lung diffusion capacity. 
Notes: spearman correlation analysis of BPIFa1 and BPIFB1 protein levels with DlCO (A, C) and KCO (B, D). R
2= determination coefficient. 
Abbreviations: BPIF protein, bactericidal/permeability-increasing fold-containing protein; DlCO, diffusing capacity of the lung for carbon monoxide; KCO, the ratio of DlCO 
to alveolar volume.
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expression of BPIFa1 and BPIFB1 in COPD patients
Table S4 general linear model for BPIFB1 protein expression
Parameter B Standard 
error
t Significance
Intercept -2.249 1.354 -1.660 0.101
age 0.014 0.02 0.679 0.499
gender
Male -0.316 0.373 -0.848 0.399
Female 0a
Inhaled corticosteroids
Inhaled corticosteroid use 0.233 0.459 0.507 0.614
no inhaled corticosteroid use 0a
smoking status
Yes 0.535 0.358 1.494 0.139
no (ex-smoker or never-smoker) 0a
COPD status
COPD III–IV 1.155 0.689 1.675 0.098
COPD II 1.412 0.403 3.502 0.001
Without COPD 0a
Notes: areference parameter is set to 0. linear regression analysis, where the natural logarithm of the protein expression of BPIFB1 is designated as the dependent variable; 
gender as a fixed factor; COPD status, smoking status, and inhaled corticosteroids as random factors; and age as a covariate.
Abbreviation: COPD, chronic obstructive pulmonary disease.
